Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: Accelerated Approval For Tecentriq And A Burst Of Filings And Submissions

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker. 
Advertisement

Related Content

Janssen’s Spravato Enters US Market With Enhanced REMS And Plans For A Monotherapy Trial
Janssen’s Esketamine Needs Better Defined REMS, US FDA Panel Says
Celgene Gives Reassurances That Key Products And Programs Remain On Track
Keeping Track: FDA's Review Actions Carry On During Shutdown
Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?
Keeping Track Of Approvals: Cancer, Cancer, And A Two-Week Cancer Review
Sage's Brexanolone Could Be Transformative, But Only In Controlled Settings, US FDA Panel Says
US FDA commissioner's hammer falls on Avastin; breast cancer use revoked
Incyte’s Jakafi Gets Broad Label, Early Approval For Myelofibrosis
Sanofi-Aventis to pay up to $560 million for single product TargeGen

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124894

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel